EU-GMP Part I certification is the single most significant compliance milestone for a Thai cannabis manufacturer targeting European markets. EU-GMP requirements are set out in EudraLex Volume 4, published by the European Commission, which defines Part I as covering finished medicinal products and Part II as covering active substances (APIs), harmonized with ICH Q7. For Thai cannabis manufacturers, Part I is required for finished medicinal products (bottled oils, capsules, packaged flower for dispensing), while Part II applies to bulk cannabis used as an API starting material for further EU processing. It is also the most commonly misunderstood. Manufacturers frequently underestimate the scope, overestimate the speed, and underestimate the cost, particularly when they begin the process without experienced guidance. This guide covers each phase realistically.
Phase 1: Gap Assessment (Weeks 1 to 6)
The process begins with a comprehensive gap assessment against EU-GMP Part I requirements. This covers the quality management system (QMS), premises and equipment qualification, personnel competency and training records, raw material controls, manufacturing procedures, quality control laboratory systems, and self-inspection programs. The gap assessment produces a prioritized remediation plan with a realistic timeline and resource estimate. Most Thai cannabis manufacturers encounter the largest gaps in documentation granularity, equipment qualification records, laboratory method validation, and formal change control systems. Identifying these gaps early is far less expensive than discovering them during a formal inspection.
Phase 2: Remediation (Months 2 to 8)
Remediation is where most of the work occurs and where most timelines slip. SOPs must be written, reviewed, approved, and implemented, not simply filed. Equipment must be formally qualified with IQ/OQ/PQ protocols, not just checked that it functions. Laboratory methods must be validated against Ph. Eur. or equivalent standards with documented validation reports. Staff training must be delivered and documented against defined competency requirements, with records showing the training was understood and applied. Experienced QP oversight during this phase significantly reduces the risk of producing documentation that looks compliant on paper but fails under inspection scrutiny.
Phase 3: Mock Inspection and Pre-Inspection Audit (Months 8 to 10)
Before submitting for a formal inspection, a mock inspection run by an experienced EU-GMP consultant or QP allows residual gaps to be identified and closed in a low-stakes environment. This phase also includes preparation of the Site Master File, a comprehensive document describing the facility, its operations, its products, and its quality systems for the inspecting authority. The Site Master File must accurately represent the facility as it will be inspected on the day, not as it is intended to be in the future.
Phase 4: Formal Inspection and Certificate Issuance (Months 10 to 12)
The formal inspection is typically conducted over 2 to 4 days for a cannabis manufacturing facility. Deficiencies are classified as critical, major, or other. Critical deficiencies preclude certification and require substantial remediation before re-inspection. Major deficiencies require corrective and preventive action (CAPA) responses and timely closure but do not automatically fail the inspection if addressed credibly. With a well-prepared facility and no critical findings, certificate issuance follows within weeks of inspection close-out documentation.
The QP Role in EU-GMP
A Qualified Person registered with the relevant EU competent authority sits on the EU importer's side and is legally responsible for formally releasing each batch of imported cannabis for the EU market. The QP reviews the batch documentation, the certificate of analysis from an accredited laboratory, and the manufacturing authorization of the Thai supplier before releasing the product for distribution. Having a QP with direct knowledge of the Thai supply chain (facility, processes, documentation standards, and audit history) significantly improves the reliability and speed of the release process.
DeeMED Consulting structures EU-GMP programs with defined milestones and QP oversight throughout, from gap assessment to certificate issuance. Our Qualified Person is registered with both BfArM and MHRA, based in Thailand, providing direct on-the-ground oversight aligned with the same standards European inspectors apply.
Common Reasons the Process Takes Longer Than Expected
The most frequent causes of timeline overruns are: underestimating the documentation burden during remediation (there is no shortcut to a validated, traceable QMS); equipment qualification backlogs when multiple pieces of critical equipment require qualification simultaneously; laboratory method validation taking longer than anticipated due to the complexity of Ph. Eur. cannabis monograph requirements; and change control failures where improvements made during remediation are not formally documented as changes, creating compliance gaps. Starting the process with a realistic timeline and experienced guidance avoids each of these.